New & Notable
FDA bans Red No. 3 in food and ingested drugs
On Jan. 15, 2025, the FDA revoked authorization for Red No. 3 in food and ingested drugs under the Delaney Clause of the Federal Food, Drug, and Cosmetic Act, requiring manufacturers to comply by Jan. 18, 2028.
FDA launches strategy to strengthen infant formula supply chain
The FDA's latest long-term strategy on the U.S. infant formula market addresses supply chain vulnerabilities with enhanced oversight, collaboration and market diversification.
Modernizing pharma manufacturing with AMT designation
The FDA's AMT Designation Program seeks to transform pharmaceutical manufacturing by improving drug quality, enhancing supply chain resilience and accelerating drug development timelines.
FDA draft guidance targets racial bias in pulse oximeters
On Jan. 6, 2025, the FDA issued a draft guidance to tackle racial bias in pulse oximeters, focusing on improving accuracy and performance to ensure equitable healthcare technology.
Insights
Insights is the research division of Xtelligent Healthcare Media. Our work aims to leverage Xtelligent’s diverse readership of healthcare professionals across various sectors of the industry to understand real-world challenges and identify effective solutions.
Access All Reports
Healthcare Strategies: A Podcast
-
A podcast for healthcare professionals seeking solutions to today's and tomorrow's top challenges. Hosted by the editors of Xtelligent Healthcare Media, this podcast series focuses on real-world use cases that are leading to tangible improvements in care quality, outcomes, and cost.
Guests from leading provider, payer, government, and other organizations share their approaches to transforming healthcare in a meaningful and lasting way.
View All Episodes
Latest News
-
Respiratory disease statistics show increasing infection rates
Respiratory disease statistics found on the CDC's Respiratory Illness Data Channel have shown rising rates of emergency department visits and wastewater viral activity levels.
-
FDA approves Zepbound for obstructive sleep apnea
The FDA has expanded Zepbound's indications, allowing its use beyond weight management to treat moderate-to-severe obstructive sleep apnea in patients with obesity.
-
AMA's top 10 health recommendations for 2025
As the new year approaches, the AMA has released 10 recommendations aimed at helping individuals achieve meaningful and lasting health improvements in 2025 and beyond.
-
USPSTF proposes guidelines for cervical cancer screening
With the advent of new self-collection methods for HPV testing, the USPSTF has proposed draft guidelines for cervical cancer screening that include patient-collected HPV tests.
-
ARPA-H awards startup $3 million for home preeclampsia test
Gravidas Diagnostics received $3 million from ARPA-H to develop a home fingerstick preeclampsia test that detects sFlt‐1 levels in the bloodstream using a colorimetric assay.
-
Pharmacy closures pose risk for minority communities
A study analyzing trends in pharmacy closures found that closures exceeded pharmacy openings between 2018 and 2021, disproportionately impacting marginalized communities.
Features
-
Analyzing therapeutic psychedelics: Opportunities, challenges
Experts at the 2024 WMIF discuss the challenges and opportunities associated with therapeutic psychedelics, including cost, access, continued innovation and patient management.
-
Advancing continuous manufacturing with FDA support
Continuous manufacturing is transforming pharmaceuticals with FDA support, bringing faster production, cost savings and improved quality to the industry.
-
2025 life sciences industry outlook: What's next?
A 2025 life sciences industry outlook report identifies several focus areas, including digital transformation, competitive pressures, business volatility and evolving customer needs.
-
Understanding the impact of food safety recalls, regulation
Food safety regulations are key to protecting public health, ensuring safe consumption and maintaining consumer trust amid complex global food systems.